Clinical trials: Alcoholic Liver Disease
Liver Cirrhosis, Alcoholic
Efficacy of Baclofen in the Treatment of Alcohol Addiction
Intervention to achieve alcohol abstinence represents the most effective treatment for alcoholic patients with liver cirrhosis. However no trials have evaluated the efficacy of anti-craving drugs in these patients because of the…
- Trial name
- NCT00525252
- Testing
- Baclofen
- Volunteers
- 86 people
- Sponsor
- Catholic University of the Sacred Heart
Morbid Obesity, Insulin Resistance
Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery
The purpose of this research is to further study the effect weight loss after gastric bypass surgery has on the heart and blood pressure and on how the body uses or metabolizes the sugars, fats and proteins we eat.
- Conditions
- Morbid Obesity, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT01007955
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Massachusetts, Worcester
Non-Alcoholic Fatty Liver Disease
Effect of Molecular Hydrogen in Patients With NAFLD
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective…
- Trial name
- EMoHyNAFLD (NCT05325398)
- Testing
- HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada
- Where
- Slovakia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Comenius University
Alcoholic Hepatitis
IL-1 Signal Inhibition in Alcoholic Hepatitis
Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption.
- Trial name
- ISAIAH (NCT03775109)
- Testing
- Canakinumab 150mg/ml solution for injection
- Where
- 16 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- Imperial College London
NAFLD
Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study is to test a non-invasive imaging technique to reliably diagnose NAFLD in children and adolescents with obesity and assess the degree of fibrosis.
- Trial name
- NAFLD (NCT03587298)
- Testing
- Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Non Alcoholic Steatohepatitis
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
The study was being conducted in order to assess the pharmacokinetics and the safety of elafibranor following once daily administration of two dose levels of elafibranor (80 milligrams [mg] and 120mg) during 3 months in children…
- Trial name
- NCT03883607
- Testing
- Elafibranor 80mg, Elafibranor 120mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Genfit
Fatty Liver Without Mention of Alcohol
A Clinical Study of Curcuvail® in Patients With Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. It comprises a wide spectrum of disorders that range from simple steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis…
- Trial name
- NAFLD (NCT06256926)
- Testing
- Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)
- Where
- India
- Volunteers
- 30 people
- Sponsor
- COD Research Private Ltd
ALD - Alcoholic Liver Disease
Comparison of ALD, NASH, and Healthy Control Patients
The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in…
- Trial name
- NCT03224949
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
NASH - Nonalcoholic Steatohepatitis
Spironolactone Therapy In Young Women With NASH
Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years.
- Trial name
- NCT03576755
- Testing
- Spironolactone 100mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Fatty Liver, Hepatitis
Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine if orlistat (Xenical) therapy in overweight patients with NASH leads to enhanced weight loss over time, with subsequent improvement in the underlying necroinflammatory and fibrotic…
- Trial name
- NCT00160407
- Testing
- Orlistat (Xenical), 1400 kcal diet (30% fat)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- St. Louis University
Obstructive Sleep Apnea, Non-alcoholic Fatty Liver Disease
Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease
To study the frequency of obstructive sleep apnea (OSA) and continuous positive airway pressure (CPAP) treatment response in patients with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT02728765
- Testing
- Continuous positive airway pressure (CPAP)
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- Chinese University of Hong Kong
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
This study is conducted to test the hypothesis that in type 2 diabetic adults with fatty liver who are resistant to metformin, treatment with liraglutide in combination with metformin will cause an absolute reduction in liver fat…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Type 2 Diabetes
- Trial name
- LIRAINS (NCT01399645)
- Testing
- Liraglutide-metformin vs insulin-metformin
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease
The purpose of this study is to investigate the effect of weight loss rate on liver steatosis, steatohepatitis, fibrosis and cardiovascular risk at different stages before and after bariatric surgery.
- Trial name
- NCT01828528
- Testing
- Sleeve gastrectomy
- Where
- Israel
- Volunteers
- 26 people
- Sponsor
- Sheba Medical Center
NAFLD
Target of Suv420h1/2 in Hepatocytes
Nonalcoholic fatty liver disease (NAFLD) is globally the leading cause of liver disease and frequently progresses to cirrhosis and liver cancer. The identification of effective drugs is the main unmet clinical need.
- Trial name
- NCT06332677
- Testing
- the main genes and expression by comparing the transcriptomic lipidomic profile
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Non-alcoholic Steatohepatitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).
- Trial name
- BANFF (NCT04171765)
- Testing
- BFKB8488A
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
NAFLD (Nonalcoholic Fatty Liver Disease)
A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.
The goal of this clinical trial is to learn if drugs Dapagliflozin and Empagliflozin work to treat NAFLD in Type 2 diabetes patients. It will also learn about the safety of drugs dapagliflozin and empagliflozin.
- Trial name
- (Dapa)& (Empa) (NCT07363707)
- Testing
- Dapagliflozin + Metformin, Empa
- Where
- Egypt
- Volunteers
- 108 people
- Sponsor
- Beni-Suef University
Liver Transplant; Complications, Diabetes Mellitus
Semaglutide vs Sitagliptin
The effect of once daily dosing of oral Semaglutide versus once daily dosing Sitagliptin on glycemic control, body weight, and safety and tolerability will be compared in Liver Transplant Recipients with poorly-controlled…
- Conditions
- Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT05195944
- Testing
- Semaglutide Treatment, Sitagliptin 100mg
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- University Health Network, Toronto
NASH - Nonalcoholic Steatohepatitis, Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
This is a single centre, open label, randomized, 3 treatment arms, with and without food dosing, Phase 1b pharmacology study to assess the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Farnesoid X…
- Trial name
- NCT03976687
- Testing
- EYP001a
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Non-Alcoholic Fatty Liver Disease
Electrical Impedance Tomography in Fatty Liver Detection
Non-alcoholic fatty liver disease (NAFLD) is a condition where hepatocytes contain an abnormally high fat percentage. This condition is becoming increasingly common due to unhealthy food habits and sedentary lifestyle.
- Trial name
- NCT05189990
- Testing
- Electrical impedance tomography
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
Chronic Liver Disease, Fibrosis, Liver
Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity
The aims of this study are to assess the performance of the non-invasive Electrical Impedance Technology (EIT) in evaluating the liver fibrosis stage in patients with chronic liver diseases, in comparisons with a liver biopsy…
- Conditions
- Chronic Liver Disease, Fibrosis, Liver, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03492879
- Testing
- EIT Technology
- Volunteers
- 210 people
- Sponsor
- Prof. Ziv Ben-Ari MD